MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, announced today the availability of a corporate video presentation outlining the Company’s leadership in the field of innovative, organic biocompatible stent coatings based on a proprietary HAp platform technology.
“MIVT is developing a novel hydroxyapatite-based technology to create ultra-thin coatings for passive and drug-eluting applications for vascular stents, which are used to prop open clogged or narrowed arteries and restore healthy blood flow, and other medical devices,” said Mr. Lindsay.
Full news
